Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation

PharmacoEconomics
Craig I ColemanPrabashni Reddy

Abstract

In the Treatment with Ibutilide and Magnesium Evaluation (TIME) study, a retrospective multicentre cohort trial, prophylactic magnesium was found to improve the antiarrhythmic efficacy of ibutilide as demonstrated by an increase in the rate of successful chemical conversion and reduction in the need for direct current cardioversion (DCC). The primary objective of this piggyback cost-effectiveness analysis of the TIME study was to compare the cost per successful conversion of atrial fibrillation (AF) for ibutilide in the presence and absence of magnesium prophylaxis. A secondary objective was to determine whether specific factors predict costs in the conversion of AF. The study was conducted from the US hospital-payer perspective. Direct medical costs (USD, 2002 values) including drugs, intravenous admixture and administration, DCC, electrocardiographs and physicians' fees were obtained directly from the provider. Nonparametric bootstrapping was conducted to calculate confidence intervals for the incremental cost-effectiveness ratios. One-way sensitivity analysis was conducted varying efficacy, and drug, hospital and physician costs. Multivariate analysis was conducted to determine whether specific baseline factors were predicto...Continue Reading

References

Feb 1, 1988·Circulation·D TzivoniS Stern
Aug 1, 1994·Risk Analysis : an Official Publication of the Society for Risk Analysis·D E Burmaster, P D Anderson
Jul 29, 1998·Medical Decision Making : an International Journal of the Society for Medical Decision Making·M G HuninkM C Weinstein
Apr 28, 2000·BMJ : British Medical Journal·S G Thompson, J A Barber
Dec 1, 2000·The Annals of Pharmacotherapy·A B DunnJ Kluger
Apr 6, 2004·The Annals of Thoracic Surgery·James S KalusJeffrey Kluger

❮ Previous
Next ❯

Citations

Feb 28, 2013·PharmacoEconomics·Bernd BrüggenjürgenStefan N Willich
Apr 9, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Craig I ColemanUNKNOWN Dofetilide and Intravenous Magnesium Evaluation (DIME) Investigators
Oct 28, 2008·The Journal of Cardiovascular Nursing·Michael C GiudiciS Serge Barold
Jun 5, 2013·Pacing and Clinical Electrophysiology : PACE·Harsha V GangaJeffrey Kluger
Jul 29, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Doreen McBrideBernd Brüggenjürgen
Oct 22, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·William L Baker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.